Antonio Cavazos
The University of Texas MD Anderson Cancer Center(US)The University of Texas MD Anderson Cancer Center(US)AbbVie (United States)(US)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Histone Deacetylase Inhibitors Research, Acute Lymphoblastic Leukemia research
Most-Cited Works
- → Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models(2020)138 cited
- → Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models(2019)113 cited
- → Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia(2022)60 cited
- → Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia(2017)50 cited
- → Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia(2018)49 cited
- → Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells(2022)42 cited